GUELPH, Ont. — PlantForm Corporation has engaged Landmark Capital Corporation as a strategic advisor in conjunction with the company’s $20 million equity financing to develop and market its plant-based technology platform for ultra-low-cost therapeutic antibody drugs.

Landmark Capital is a boutique investment bank based in Greenwich, CT, which will advise PlantForm and identify sources of institutional equity for the company.

“PlantForm is raising equity financing to proceed to human clinical trials of our first product, plant-produced trastuzumab, a subsequent-entry-biologic version of the Roche Group’s breast cancer drug Herceptin®,” said Don Stewart, PlantForm President and CEO. “We’re pleased to be working with Landmark to achieve this next major milestone on our way to market entry.”

The engagement is exclusive to the United States and includes PlantForm’s participation in the Landmark Venture Forum in Greenwich, CT on Sept. 22 and Landmark’s ‘Investing for Cures’ conference on Nov. 9 in New York City.

“We are pleased to be working with Don Stewart and the rest of the PlantForm management team as the company’s innovative biologic antibody technology has the potential to significantly reduce the cost of therapeutics for the treatment of cancers and other major diseases,” said William S. Podd, President and CEO of Landmark Capital.

PlantForm Corporation’s mission is to provide low-cost, subsequent-entry-biologic (biosimilar) antibody drugs to treat cancer and other critical illnesses. The company licenses its proprietary manufacturing platform from the University of Guelph, where it was developed by Dr. J. Christopher Hall, PlantForm’s Chief Scientific Officer and the Canada Research Chair in Recombinant Antibody Technology. All relevant intellectual property is protected by patent filings.

For more information, please contact:

Don Stewart
President and CEO
don.stewart@plantformcorp.com
(416) 452-7242

Stacey Curry Gunn
Communications
stacey.curry_gunn@plantformcorp.com
(519) 827-1131

www.plantformcorp.com